Q2 2026 EPS Estimates for Agilent Technologies, Inc. Boosted by Analyst (NYSE:A)

Agilent Technologies, Inc. (NYSE:A) – Investment analysts at Zacks Research increased their Q2 2026 EPS estimates for Agilent Technologies in a research note issued to investors on Wednesday, June 19th. Zacks Research analyst S. Mete now expects that the medical research company will post earnings per share of $1.53 for the quarter, up from their previous estimate of $1.49. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.25 per share. Zacks Research also issued estimates for Agilent Technologies’ FY2026 earnings at $6.42 EPS.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, May 29th. The medical research company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.03. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.58 billion. During the same period in the previous year, the business earned $1.27 EPS. The firm’s revenue for the quarter was down 8.4% on a year-over-year basis.

Other research analysts also recently issued research reports about the stock. TD Cowen dropped their target price on shares of Agilent Technologies from $163.00 to $153.00 and set a “buy” rating for the company in a report on Thursday, May 30th. Citigroup dropped their target price on shares of Agilent Technologies from $145.00 to $135.00 and set a “neutral” rating for the company in a report on Thursday, May 30th. JPMorgan Chase & Co. dropped their target price on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating for the company in a report on Thursday, May 30th. Bank of America reaffirmed a “neutral” rating and issued a $134.00 target price (down previously from $145.00) on shares of Agilent Technologies in a report on Thursday, May 30th. Finally, Evercore ISI dropped their target price on shares of Agilent Technologies from $145.00 to $126.00 and set an “in-line” rating for the company in a report on Thursday, May 30th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $136.50.

Agilent Technologies Trading Up 0.4 %

NYSE:A opened at $133.25 on Monday. The company has a current ratio of 2.15, a quick ratio of 1.64 and a debt-to-equity ratio of 0.34. Agilent Technologies has a 12 month low of $96.80 and a 12 month high of $155.35. The company has a market cap of $38.88 billion, a PE ratio of 31.50, a price-to-earnings-growth ratio of 4.50 and a beta of 1.07. The company has a 50 day simple moving average of $139.83 and a two-hundred day simple moving average of $138.39.

Institutional Trading of Agilent Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Gotham Asset Management LLC grew its position in shares of Agilent Technologies by 246.7% in the third quarter. Gotham Asset Management LLC now owns 54,437 shares of the medical research company’s stock valued at $6,087,000 after purchasing an additional 38,737 shares during the period. UBS Group AG grew its position in shares of Agilent Technologies by 84.5% in the fourth quarter. UBS Group AG now owns 325,695 shares of the medical research company’s stock valued at $45,281,000 after purchasing an additional 149,159 shares during the period. TD Asset Management Inc grew its position in shares of Agilent Technologies by 27.1% in the fourth quarter. TD Asset Management Inc now owns 1,609,420 shares of the medical research company’s stock valued at $223,758,000 after purchasing an additional 343,175 shares during the period. DAVENPORT & Co LLC grew its position in shares of Agilent Technologies by 77.7% in the fourth quarter. DAVENPORT & Co LLC now owns 4,882 shares of the medical research company’s stock valued at $679,000 after purchasing an additional 2,135 shares during the period. Finally, Meritage Group LP grew its position in shares of Agilent Technologies by 28.3% in the fourth quarter. Meritage Group LP now owns 2,116,862 shares of the medical research company’s stock valued at $294,307,000 after purchasing an additional 467,451 shares during the period.

Insiders Place Their Bets

In other Agilent Technologies news, SVP Dominique Grau sold 15,000 shares of the firm’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $133.28, for a total value of $1,999,200.00. Following the completion of the transaction, the senior vice president now owns 49,486 shares of the company’s stock, valued at $6,595,494.08. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total transaction of $254,540.00. Following the completion of the transaction, the chief executive officer now owns 25,185 shares of the company’s stock, valued at $3,274,050. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Dominique Grau sold 15,000 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the transaction, the senior vice president now directly owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The disclosure for this sale can be found here.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 24th. Shareholders of record on Tuesday, July 2nd will be issued a $0.236 dividend. The ex-dividend date is Tuesday, July 2nd. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.71%. Agilent Technologies’s dividend payout ratio is currently 22.22%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.